Length-weight relationships of coral reef fishes from the Alacran Reef, Yucatan, Mexico

Length-weight relationships were computed for 42 species of coral reef fishes from 14 families from the Alacran Reef (Yucatan, Mexico). A total of 1 892 individuals was used for this purpose. The fish species were caught by different fishing techniques such as fishhooks, harpoons, gill and trawl nets. The sampling period was from March 1998 to January 2000

Effects of Probiotic Bacillus sp. on Food Convertion and Growth of Catfish Pangasius hypophthalmus

A triplicate experiment was conducted to evaluate the addition of probiotic Bacillus sp. into the diet on feed convertion and growth of catfish Pangasius hypophthalmus. Twenty fish with an initial body weight of 1,85 ± 0,09 g were stocked in a 60-1 aquarium. During rearing period, fish were fed on the diet three times a day at satiation. Prior the feeding, probiotic (contained Bacillus sp. 4,2x106 CFU.ml-1) were added into the diet at a dosage of 0, 5, 15 or 25 ml.kg-1 diet. The probiotic were added once a day at the noon. The results showed that maximum protein retention, lipid retention, growth rate, and minimum feed convertion was found in the group of fish fed on the diet supplemented with 15 ml probiotic kg-1 diet. Irrespective to the dosage of probiotic, food consumption and survival rate of fish were the same among the treatments. Key words : Probiotic. Bacillus sp.. catfish Pangasius hypophthalmus.   ABSTRAK Penelitian ini bertujuan untuk mengetahui dosis yang optimal dari probiotik Bacillus sp. yang ditambahkan pada pakan komersil terhadap konversi pakan dan pertumbuhan benih ikan patin Pangasius hypophthalmus. Dua puluh ekor ikan patin dengan bobot rata-rata 1.85 ± 0,09 g ditebar dalam setiap akuarium frekuensi 50x40x35 cm yang diisi air 60 1. Selama 40 had masa pemeliharaan. ikan diberi pakan buatan berkadar protein 27% dengan frekwensi tiga kali sehari, at satiation. Sebelum diberikan ke ikan, pakan tersebut ditambah produk probiotik (mengandung Bacillus sp. 4,2 x 106 CFU/ml) dengan dosis 0, 5, 15 atau 25 ml/kg pakan. Pakan yang mengandung probiotik hanya diberikan sekali setiap hari, yakni pada pukul 13.00. Hasil penelitian menunjukkan bahwa adanya penambahan probiotik dalam pakan sampai dosis 15 ml/kg pakan menyebabkan terjadinya peningkatan retensi protein, retensi lemak dan laju pertumbuhan harian ikan, serta menurunkan konversi pakan. Penambahan probiotik lebih lanjut (25 ml/kg pakan) menurunkan kinerja pertumbuhan di atas. Sementara itu. kelompok ikan di setiap perlakuan mengkonsumsi pakan dalam jumlah yang tidak berbeda nyata, yaitu antara 132,43 g sampai 137,84 g. Hasil penelitian juga menunjukkan bahwa penambahan probiotik di dalam pakan tidak memberikan adanya perbedaan yang nyata terhadap tingkat kelangsungan hidup ikan, yaitu antara 98,3% - 100%. Kata kunci: Probiotik. Bacillus sp.. ikan patin Pangasius hypophthalmu

A Multi-Stage CTLE Design and Optimization for PCI Express Gen6.0 Link Equalization

The continuously increasing bandwidth demand from new applications has led to the development of the new peripheral component interconnect express (PCIe) Gen6, reaching data rates of 64 giga-transfers per second (GT/s) and adopting the pulse amplitude modulation 4-level (PAM4) signaling scheme. While PAM4 solves the bandwidth requirements, it brings new challenges for the physical channel design. PAM4 is more susceptible to errors due to various noise sources caused by reduced voltage (and timing) ranges, yielding a higher bit error rate (BER). It also introduces new challenges in slicers, transition jitter, and equalizers, making of equalization (EQ) a critical process for PAM4 signaling. In this paper, we propose a multi-stage continuous-time linear equalizer (CTLE) with high-band, mid-band, and low-band frequency boost stages to deal with highly lossy channels. Given the complexity of EQ of multi-level signals, optimization techniques are used, including an efficient optimization of the transmitter finite impulse response (FIR) filter and the receiver CTLE tuning.ITESO, A.C

A new spin-anisotropic harmonic honeycomb iridate

The physics of Mott insulators underlies diverse phenomena ranging from high temperature superconductivity to exotic magnetism. Although both the electron spin and the structure of the local orbitals play a key role in this physics, in most systems these are connected only indirectly --- via the Pauli exclusion principle and the Coulomb interaction. Iridium-based oxides (iridates) open a further dimension to this problem by introducing strong spin-orbit interactions, such that the Mott physics has a strong orbital character. In the layered honeycomb iridates this is thought to generate highly spin-anisotropic interactions, coupling the spin orientation to a given spatial direction of exchange and leading to strongly frustrated magnetism. The potential for new physics emerging from such interactions has driven much scientific excitement, most recently in the search for a new quantum spin liquid, first discussed by Kitaev \cite{kitaev_anyons_2006}. Here we report a new iridate structure that has the same local connectivity as the layered honeycomb, but in a three-dimensional framework. The temperature dependence of the magnetic susceptibility exhibits a striking reordering of the magnetic anisotropy, giving evidence for highly spin-anisotropic exchange interactions. Furthermore, the basic structural units of this material suggest the possibility of a new family of structures, the `harmonic honeycomb' iridates. This compound thus provides a unique and exciting glimpse into the physics of a new class of strongly spin-orbit coupled Mott insulators.Comment: 12 pages including bibliography, 5 figure

Genomic DNA transposition induced by human PGBD5

Transposons are mobile genetic elements that are found in nearly all organisms, including humans. Mobilization of DNA transposons by transposase enzymes can cause genomic rearrangements, but our knowledge of human genes derived from transposases is limited. In this study, we find that the protein encoded by human PGBD5, the most evolutionarily conserved transposable element-derived gene in vertebrates, can induce stereotypical cut-and-paste DNA transposition in human cells. Genomic integration activity of PGBD5 requires distinct aspartic acid residues in its transposase domain, and specific DNA sequences containing inverted terminal repeats with similarity to piggyBac transposons. DNA transposition catalyzed by PGBD5 in human cells occurs genome-wide, with precise transposon excision and preference for insertion at TTAA sites. The apparent conservation of DNA transposition activity by PGBD5 suggests that genomic remodeling contributes to its biological function

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

BackgroundAdjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC.MethodsWe did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC. We enrolled patients from across the US National Clinical Trials Network, including patients from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) affiliates in Europe and from the Canadian Cancer Trials Group, within 6-12 weeks of surgery. The chemotherapy regimen for each patient was selected before randomisation and administered intravenously; it consisted of four 21-day cycles of cisplatin (75 mg/m2 on day 1 in all regimens) in combination with investigator's choice of vinorelbine (30 mg/m2 on days 1 and 8), docetaxel (75 mg/m2 on day 1), gemcitabine (1200 mg/m2 on days 1 and 8), or pemetrexed (500 mg/m2 on day 1). Patients in the bevacizumab group received bevacizumab 15 mg/kg intravenously every 21 days starting with cycle 1 of chemotherapy and continuing for 1 year. We randomly allocated patients (1:1) to group A (chemotherapy alone) or group B (chemotherapy plus bevacizumab), centrally, using permuted blocks sizes and stratified by chemotherapy regimen, stage of disease, histology, and sex. No one was masked to treatment assignment, except the Data Safety and Monitoring Committee. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00324805.FindingsBetween June 1, 2007, and Sept 20, 2013, 1501 patients were enrolled and randomly assigned to the two treatment groups: 749 to group A (chemotherapy alone) and 752 to group B (chemotherapy plus bevacizumab). 383 (26%) of 1458 patients (with complete staging information) had stage IB, 636 (44%) had stage II, and 439 (30%) had stage IIIA disease (stage of disease data were missing for 43 patients). Squamous cell histology was reported for 422 (28%) of 1501 patients. All four cisplatin-based chemotherapy regimens were used: 377 (25%) patients received vinorelbine, 343 (23%) received docetaxel, 283 (19%) received gemcitabine, and 497 (33%) received pemetrexed. At a median follow-up of 50·3 months (IQR 32·9-68·0), the estimated median overall survival in group A has not been reached, and in group B was 85·8 months (95% CI 74·9 to not reached); hazard ratio (group B vs group A) 0·99 (95% CI 0·82-1·19; p=0·90). Grade 3-5 toxicities of note (all attributions) that were reported more frequently in group B (the bevacizumab group) than in group A (chemotherapy alone) were overall worst grade (ie, all grade 3-5 toxicities; 496 [67%] of 738 in group A vs 610 [83%] of 735 in group B), hypertension (60 [8%] vs 219 [30%]), and neutropenia (241 [33%] vs 275 [37%]). The number of deaths on treatment did not differ between the groups (15 deaths in group A vs 19 in group B). Of these deaths, three in group A and ten in group B were considered at least possibly related to treatment.InterpretationAddition of bevacizumab to adjuvant chemotherapy did not improve overall survival for patients with surgically resected early-stage NSCLC. Bevacizumab does not have a role in this setting and should not be considered as an adjuvant therapy for patients with resected early-stage NSCLC.FundingNational Cancer Institute of the National Institutes of Health

A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer

PURPOSE: Stage III non-small cell lung cancer (NSCLC) patients with poor performance status (PS) or co-morbidities are often not candidates for standard chemoradiotherapy (chemoRT) due to poor tolerance to treatments. A pilot study for poor-risk stage III NSCLC patients was conducted combining cetuximab, a chimeric monoclonal antibody targeting epidermal growth factor receptor (EGFR), with chest radiation (RT). METHODS: Stage III NSCLC patients with Zubrod PS 2, or Zubrod PS 0-1 with poor pulmonary function and co-morbidities prohibiting chemoRT were eligible. A loading dose of cetuximab (400 mg/m(2)) was delivered week 1, followed by weekly cetuximab (250 mg/m(2))/RT to 64.8 Gy in 1.8 Gy daily fractions, and maintenance weekly cetuximab (250 mg/m(2)) for 2 years or until disease progression. H-score for EGFR protein expression was conducted in available tumors. RESULTS: Twenty-four patients were enrolled. Twenty-two were assessed for outcome and toxicity. Median survival was 14 months and median progression-free survival was 8 months. The response rate was 47% and disease control rate was 74%. Toxicity assessment revealed 22.7% overall \u3e /=Grade 3 non-hematologic toxicities. Grade 3 esophagitis was observed in one patient (5%). The skin reactions were mostly Grade 1 or 2 except two of 22 (9%) had Grade 3 acne and one of 22 (5%) had Grade 3 radiation skin burn. Grade 3-4 hypomagnesemia was seen in four (18%) patients. One patient (5%) had elevated cardiac troponin and pulmonary emboli. H-score did not reveal prognostic significance. An initially planned second cohort of the study did not commence due to slow accrual, which would have added weekly docetaxel to cetuximab/RT after completion of the first cohort of patients. CONCLUSION: Concurrent weekly cetuximab/chest RT followed by maintenance cetuximab for poor-risk stage III NSCLC was well tolerated. Further studies with larger sample sizes will be useful to establish the optimal therapeutic ratio of this regimen

The Influence of In Vitro Gastrointestinal Digestion on the Anticancer Activity of Manuka Honey

Manuka honey (MH) is a natural food with many beneficial properties to human health, thanks to its high variety of bioactive compounds; however, little is known about its bioaccessibility. The aim of this study was to evaluate and compare the polyphenol compounds, the antioxidant capacity and the anticancer activity of MH subjected to an in vitro gastrointestinal digestion in human HCT-116 colon cancer cells. Raw MH and digested MH (DMH) were assessed for total polyphenols and flavonoids by spectrophotometric and HPLC-ESI-MS/MS analysis, and total antioxidant capacity (TAC) using different methods. Cell viability, intracellular ROS production, apoptosis, cell cycle and colony formation capacity were tested after treatment with MH or DMH. Results showed that total polyphenols, total flavonoids and TAC were significantly (p < 0.05) reduced after in vitro digestion. In addition, MH and DMH at 8, 16 and 24 mg/mL had similar effects in inducing intracellular ROS production and in inhibiting the colon formation ability; MH induced a more marked apoptosis compared to DMH, while cell cycle was blocked in S phase by MH and in Sub G1 phase by DMH. Our results increase knowledge of the effect of gastrointestinal digestion on the biological effect of honey against colorectal cancer